Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background: The presence of telomerase reverse transcriptase (TERT) promoter mutations have been associated with a poor prognosis in patients with papillary thyroid carcinomas (PTC). The frequency of TERT promoter mutations varies widely depending on the population and the nature of the study. Methods: Data were prospectively collected in 724 consecutive patients who underwent thyroidectomy for PTC from 2018 to 2019. Molecular testing for BRAF V600E and TERT promoter mutations was performed in all cases. Results: TERT promoter alterations in two hotspots (C228T and C250T) and C216T were found in 16 (2.2%) and 4 (0.6%) of all PTCs, respectively. The hotspot mutations were significantly associated with older age at diagnosis, larger tumor size, extrathyroidal extension, higher pathologic T category, lateral lymph node metastasis, and higher American Thyroid Association recurrence risk. The patients with C216T variant were younger and had a lower American Thyroid Association recurrence risk than those with hotspot mutations. Concurrent BRAF V600E was found in 19 of 20 cases with TERT promoter mutations. Of 518 microcarcinomas measuring ≤ 1.0 cm in size, hotspot mutations and C216T variants were detected in five (1.0%) and three (0.6%) cases, respectively. Conclusions: Our study indicates a low frequency of TERT promoter mutations in Korean patients with PTC and supports previous findings that TERT promoter mutations are more common in older patients with unfavorable clinicopathologic features and BRAF V600E. TERT promoter mutations in patients with microcarcinoma are uncommon and may have a limited role in risk stratification. The C216T variant seems to have no clinicopathologic effect on PTC.
Abstract
Background: The presence of telomerase reverse transcriptase (TERT) promoter mutations have been associated with a poor prognosis in patients with papillary thyroid carcinomas (PTC). The frequency of TERT promoter mutations varies widely depending on the population and the nature of the study. Methods: Data were prospectively collected in 724 consecutive patients who underwent thyroidectomy for PTC from 2018 to 2019. Molecular testing for BRAF V600E and TERT promoter mutations was performed in all cases. Results: TERT promoter alterations in two hotspots (C228T and C250T) and C216T were found in 16 (2.2%) and 4 (0.6%) of all PTCs, respectively. The hotspot mutations were significantly associated with older age at diagnosis, larger tumor size, extrathyroidal extension, higher pathologic T category, lateral lymph node metastasis, and higher American Thyroid Association recurrence risk. The patients with C216T variant were younger and had a lower American Thyroid Association recurrence risk than those with hotspot mutations. Concurrent BRAF V600E was found in 19 of 20 cases with TERT promoter mutations. Of 518 microcarcinomas measuring ≤ 1.0 cm in size, hotspot mutations and C216T variants were detected in five (1.0%) and three (0.6%) cases, respectively. Conclusions: Our study indicates a low frequency of TERT promoter mutations in Korean patients with PTC and supports previous findings that TERT promoter mutations are more common in older patients with unfavorable clinicopathologic features and BRAF V600E. TERT promoter mutations in patients with microcarcinoma are uncommon and may have a limited role in risk stratification. The C216T variant seems to have no clinicopathologic effect on PTC.
참고문헌 (28)
- Vaccarella S, "Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis", N Engl J Med, 375, pp.614~617 (2016)
- Ahn HS, "Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality", Thyroid, 26, pp.1535~1540 (2016)
- Ahn HS, "Korea's thyroid-cancer"epidemic" : screening and overdiagnosis", N Engl J Med, 371, pp.1765~1767 (2014)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Park S, "Association between screening and the thyroid cancer"epidemic"in South Korea : evidence from a nationwide study", BMJ, 355, pp.i5745~ (2016)
- 전민지, "Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study", Endocrinology and Metabolism, 32(4), pp.434~441 (2017), 대한내분비학회
- Lloyd RV, "WHO classification of tumours of endocrine organs", pp.65~91 (2017), International Agency for Research on Cancer (IARC)
- Liu R, "Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer : genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality", JAMA Oncol, 3, pp.202~208 (2017)
- Kim TH, "TERT promoter mutations and long-term survival in patients with thyroid cancer", Endocr Relat Cancer, 23, pp.813~823 (2016)
- Liu X, "TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer", J Clin Endocrinol Metab, 99, pp.E1130~E1136 (2014)
- Melo M, "TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas", J Clin Endocrinol Metab, 99, pp.E754~E765 (2014)
- Horn S, "TERT promoter mutations in familial and sporadic melanoma", Science, 339, pp.959~961 (2013)
- Huang FW, "Highly recurrent TERT promoter mutations in human melanoma", Science, 339, pp.957~959 (2013)
- Bae JS, "Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation", Diagn Pathol, 11, pp.21~ (2016)
- Xing M, "BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence", J Clin Oncol, 32, pp.2718~2726 (2014)
- Jung CK, "Clinical utility of EZH1mutations in the diagnosis of follicular-patterned thyroid tumors", Hum Pathol, 81, pp.9~17 (2018)
- Landa I, "Frequent somatic TERT promoter mutations in thyroid cancer : higher prevalence in advanced forms of the disease", J Clin Endocrinol Metab, 98, pp.E1562~E1566 (2013)
- Liu X, "Highly prevalent TERT promoter mutations in aggressive thyroid cancers", Endocr Relat Cancer, 20, pp.603~610 (2013)
- Song YS, "Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients", Cancer, 122, pp.1370~1379 (2016)
- Amin MB, "AJCC cancer staging manual", pp.873~890 (2017), Springer
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer", Thyroid, 26, pp.1~133 (2016)
- 정동준, "Detection of BRAFV600E Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing", Journal of Pathology and Translational Medicine, 46(1), pp.61~67 (2012), 대한병리학회
- Yang J, "Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma : a systematic review and meta-analysis", Endocrine, 67, pp.44~57 (2020)
- de Biase D, "TERT promoter mutations in papillary thyroid microcarcinomas", Thyroid, 25, pp.1013~1019 (2015)
- Yabuta T, "TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance", Thyroid, 27, pp.1206~1207 (2017)
- Ma X, "Recurrent TERT promoter mutations in non-small cell lung cancers", Lung Cancer, 86, pp.369~373 (2014)
- Zhao Y, "Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas", Int J Cancer, 134, pp.493~494 (2014)
- Song YS, "Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer", Endocr Relat Cancer, 26, pp.629~641 (2019)